Complement therapeutics; history and current progress

Molecular Immunology

Volumn 40, Issue 2-4, 2003, Pages 159-170

  Morgan, B Paul ^a   Harris, Claire L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Complement; Inflammation; Therapy

Indexed keywords

BCX 1470; COBROTOXIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPSTATIN; DEXTRAN SULFATE; EPHEDRA EXTRACT; HEPARIN; MONOCLONAL ANTIBODY; NAFAMSTAT MESILATE; POLYLYSINE; POLYVINYL DERIVATIVE; POLYVINYL SULFATE; PROTEINASE INHIBITOR; ROSMARINIC ACID; SURAMIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BACTERICIDAL ACTIVITY; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATION; ISCHEMIA; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0041563747     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00111-1     Document Type: Conference Paper

References (146)

1. Abrahamson H.A. Prevention of experimental allergic encephalomyelitis with cobra venom factor. J. Asthma Res. 8:1971;151-152.
2. Almeda S.et al. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J. Biol. Chem. 258:1983;785-791.
3. Alper C.A., Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science. 191:1976;1275-1276.
4. Asghar S.S. Pharmacological manipulation of complement system. Pharmacol. Rev. 36:1984;223-244.
5. Asghar S.S.et al. Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors. Complement. 3:1986;40-48.
6. Baker P.J.et al. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J. Immunol. 114:1975;554-558.
7. Bellelli L., Sezzi M.L. C′3 participation in the rejection of some experimental tumors. Oncology. 33:1976;215-218.
8. Biesecker G., Gomez C.M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142:1989;2654-2659.
9. Blum M.G.et al. Complement inhibition by FUT-175 and K76-COOH in a pig-to-human lung xenotransplant model. Xenotransplantation. 5:1998;35-43.
10. Brackertz D., Kueppers F. A one year's follow up of treatment of hereditary angioneurotic edema (HAE) with suramin. Allergol. Immunopathol. (Madr). 2:1974;163-168.
11. Budzko D.B.et al. Effects of complement depletion in experimental chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi. Infect. Immun. 11:1975;86-91.
12. Buerke M.et al. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J. Immunol. 167:2001;5375-5380.
13. Caldwell, J.R., 1999. Venoms, copper, and zinc in the treatment of arthritis. Rheum. Dis. Clin. North Am. 25 (viiiix), 919-928.
14. Carobbi A.et al. Suramin as an anticomplementary agent in xenotransplantation. Transplant Proc. 24:1992;700.
15. Chai P.J.et al. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation. 101:2000;541-546.
16. Chavez-Cartaya R.E.et al. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation. 59:1995;1047-1052.
17. Christiansen D.et al. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur. J. Immunol. 26:1996a;578-585.
18. Christiansen D.et al. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology. 87:1996b;348-354.
19. Cochrane C.G.et al. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:1970;55-69.
20. Cooper N.R. Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J. Exp. Med. 137:1973;451-460.
21. Couser W.G.et al. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J. Am. Soc. Nephrol. 5:1995;1888-1894.
22. Crosson F.J. Jr.et al. Participation of complement in the nonimmune host defense against experimental Haemophilus influenzae type b septicemia and meningitis. Infect. Immun. 14:1976;882-887.
23. Dodd I.et al. Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expression Purif. 6:1995;727-736.
24. Dong J.et al. Strategies for targeting complement inhibitors in ischaemia/reperfusion injury. Mol. Immunol. 36:1999;957-963.
25. Drake W.P.et al. In vivo abrogation of serum C3 and C5 by administration of cobra venom factor and heterologous anti-C3. J. Immunol. Methods. 6:1974;61-72.
26. Edens R.E.et al. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology. 27:1994;145-153.
27. Englberger W.et al. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity. Int. J. Immunopharmacol. 10:1988;729-737.
28. Eror A.T.et al. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin. Immunol. 90:1999;266-275.
29. Evans M.J.et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol. Immunol. 32:1995;1183-1195.
30. Fiane A.E. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 6:1999;52-65.
31. Fitch J.C.et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 100:1999;2499-2506.
32. Flexner S., Noguchi H. Snake venom in relation to hemolysis, bacteriolysis and toxicity. J. Exp. Med. 6:1903;277-301.
33. Forbes R.D.et al. The effect of anticomplementary cobra venom factor on hyperacute rat cardiac allograft rejection. Lab. Investig. 39:1978;463-470.
34. Fraser D.A.et al. Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic. Protein Sci. 11:2002;2512-2521.
35. Fujii S., Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta. 661:1981;342-345.
36. Fujita Y.et al. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Nippon Jinzo Gakkai Shi. Jpn. J. Nephrol. 35:1993;393-397.
37. Gelfand J.A.et al. Role of complement in host defense against experimental disseminated candidiasis. J. Infect. Dis. 138:1978;9-16.
38. Germuth F.G. Jr.et al. Antibasement membrane disease. II. Mechanism of glomerular injury in an accelerated model of Masugi nephritis. Lab. Investig. 39:1978;421-429.
39. Gewurz H.et al. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation. 5:1967;1296-1303.
40. Gilbert D.N.et al. Escherichia coli bacteremia in the squirrel monkey. I. Effect of cobra venom factor treatment. J. Clin. Investig. 52:1973;406-413.
41. Glover G.I.et al. Synthetic peptide inhibitors of complement serine proteases-I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D. Mol. Immunol. 25:1988;1261-1267.
42. Goodfellow, R.M., et al. 1999. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin. Exp> Immunol. 119.
43. Goodfellow R.M., Williams A.S., Levin J.L., Williams B.D., Morgan B.P. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat monoarticular arthritis. Clin. Exp. Immunol. 110:1997;45-52.
44. Guckian J.C.et al. The role of opsonins in recovery from experimental pneumococcal pneumonia. J. Infect. Dis. 142:1980;175-190.
45. Harig F.et al. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac. Cardiovasc. Surg. 47:1999;111-118.
46. Harris C.L.et al. Tailoring anti-complement therapeutics. Biochem. Soc. Trans. 30:2002a;1019-1026.
47. Harris C.L.et al. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin. Exp. Immunol. 129:2002b;198-207.
48. Hays S.J.et al. 2-Amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease. J. Med. Chem. 41:1998;1060-1067.
49. Hebell T.et al. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science. 254:1991;102-105.
50. Henry S.P.et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2:2002;1657-1666.
51. Heyer E.J.et al. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J. Cardiothorac. Vasc. Anesth. 16:2002;37-42.
52. Higgins P.J.et al. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J. Immunol. 158:1997;2872-2881.
53. Hill J.et al. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149:1992;1723-1728.
54. Hirsch R.L.et al. The role of complement in viral infections. II. The clearance of Sindbis virus from the bloodstream and central nervous system of mice depleted of complement. J. Infect. Dis. 141:1980;212-217.
55. Hitomi Y., Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int. Arch. Allergy Appl. Immunol. 69:1982;262-267.
56. Holden C. Flurry over venom. Science. 207:1980;161.
57. Hong K.et al. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J. Immunol. 127:1981;104-108.
58. Huang J.et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science. 285:1999;595-599.
59. Hughes-Jones N.C., Gardner B. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology. 34:1978;459-463.
60. Inagi R.et al. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol. Lett. 27:1991;49-52.
61. Ino Y.et al. Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation. Gen. Pharmacol. 18:1987;513-516.
62. Jung S.et al. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci. Lett. 200:1995;167-170.
63. Kallio E.A.et al. Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts. Am. J. Respir. Crit. Care Med. 161:2000;1332-1339.
64. Kaplan M. Eculizumab (Alexion). Curr. Opin. Investig. Drugs. 3:2002;1017-1023.
65. Kozlov L.V.et al. Inhibition of the binding and activation of the first component of human complement. The effect of synthetic peptides, immunoglobulin fragments and various proteins. Biokhimiia. 51:1986;707-718.
66. Kroshus T.J.et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation. 60:1995;1194-1202.
67. Kroshus T.J.et al. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation. 69:2000;2282-2289.
68. Lehmann T.G.et al. Impact of inhibition of complement by sCR1 on hepatic microcirculation after warm ischemia. Microvasc. Res. 62:2001;284-292.
69. Lennon V.A.et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147:1978;973-983.
70. Ling M.et al. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. Clin. Exp. Immunol. 102:1995;582-588.
71. Linton S.M.et al. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arth. Rheum. 43:2000;2590-2597.
72. Maillard J.L., Zarco R.M. Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat. Ann. Inst. Pasteur Paris. 114:1968;756-774.
73. Maini R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51:2000;207-229.
74. Makrides S.C.et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J. Pharmacol. Exp. Ther. 277:1996;534-542.
75. Maroko P.R.et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J. Clin. Investig. 61:1978;661-670.
76. Martinelli G.P.et al. Studies of immunosuppression by cobra venom factor. I. On early IgG and IgM responses to sheep erythrocytes and DNP-protein conjugates. J. Immunol. 121:1978;2043-2047.
77. Metcalfe R.A.et al. The effect of soluble complement receptor 1 (sCR1) and human thyroid antibodies on the course of experimental autoimmune thyroiditis in rats. Autoimmunity. 23:1996;1-8.
78. Miyagawa S.et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation. 55:1993;709-713.
79. Miyata T.et al. Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet. 341:1993;1353.
80. Miyazaki W.et al. Effects of K-76 monocarboxylic acid, an anticomplementary agent, on various in vivo immunological reactions and on experimental glomerulonephritis. Complement. 1:1984;134-146.
81. Mizoguchi Y., Osler A.G. Effect of cobra venom factor on the response of Wistar-Furth rats to the Gross-virus-induced (C58NT)D lymphoma. Int. Arch. Allergy Appl. Immunol. 58:1979;302-312.
82. Mizuno M.et al. Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming. Int. Arch. Allergy Immunol. 127:2002;55-62.
83. Moran P.et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol. 149:1992;1736-1743.
84. Morariu M.A., Dalmasso A.P. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann. Neurol. 4:1978;427-430.
85. Morikis D., Lambris J.D. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem. Soc. Trans. 30:2002;1026-1036.
86. Mossakowska D.et al. Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation. Eur. J. Immunol. 29:1999;1955-1965.
87. Muller-Eberhard H.J., Fjellstrom K.E. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J. Immunol. 107:1971;1666-1672.
88. Mulligan M.S.et al. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewis(x) moieties. J. Immunol. 162:1999;4952-4959.
89. Narayana, S.V., et al. 2000. Inhibition of complement serine proteases as a therapeutic strategy. In: Lambris, J.D., Holers, V.M. (Eds.), Therapeutic Interventions in the Complement System. Humana, Totowa, New Jersey, pp. 57-74.
90. Nishizawa H.et al. Soluble complement receptor type 1 inhibited the systemic organ injury caused by acid instillation into a lung. Anesthesiology. 85:1996;1120-1128.
91. Opal S.M.et al. Antithrombin, heparin, and heparan sulfate. Crit. Care Med. 30:2002;S325-S331.
92. Ovrum E.et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann. Thorac. Surg. 60:1995;1755-1761.
93. Pabst H.et al. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc. Soc. Exp. Biol. Med. 136:1971;555-560.
94. Pepys M.B.et al. Role of complement in induction of antibody production in vivo. Effect of cobra venom factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J. Exp. Med. 140:1974;126-145.
95. Phillips G.B. Studies on a hemolytic factor of cobra venom requiring a heat-labile serum factor. Biochim. Biophys. Acta. 201:1970;364-374.
96. Piddlesden S.J.et al. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:1994;5477-5484.
97. Piddlesden S.J.et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71:1996;173-177.
98. Pierre A.F.et al. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation. 66:1998;723-732.
99. Pratt J.R.et al. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol. 149:1996;2055-2066.
100. Pruitt S.K.et al. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation. 52:1991;868-873.
101. Pruitt S.K.et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation. 57:1994;363-370.
102. Prystowsky M.B.et al. Inhibition of the classical complement pathway by synthetic peptides from the second constant domain of the heavy chain of human immunoglobulin G. Biochemistry. 20:1981;6349-6356.
103. Pugsley M.K. Etanercept. Immunex. Curr. Opin. Investig. Drugs. 2:2001;1725-1731.
104. Quigg R.J.et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160:1998;4553-4560.
105. Rehrig S.et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J. Immunol. 167:2001;5921-5927.
106. Rinder C.S.et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Investig. 96:1995;1564-1572.
107. Rinder, C.S., et al. 1999. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J. Thorac. Cardiovasc. Surg. 118.
108. Rioux P. TP-10 (AVANT immunotherapeutics). Curr. Opin. Investig. Drugs. 2:2001;364-371.
109. Rittershaus C.W.et al. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274:1999;11237-11244.
110. Roos A.et al. Specific inhibition of the classical complement pathway by C1q-binding peptides. J. Immunol. 167:2001;7052-7059.
111. Rudofsky U.H.et al. Inhibition of experimental autoimmune renal tubulointerstitial disease in guinea pigs by depletion of complement with cobra venom factor. Clin. Immunol. Immunopathol. 3:1975;396-407.
112. Rumjanek V.M.et al. Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor. Immunology. 34:1978;1117-1123.
113. Sahu A.et al. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157:1996;884-891.
114. Sahu A.et al. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem. Pharmacol. 57:1999;1439-1446.
115. Sahu A.et al. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol. Immunol. 39:2003;557-566.
116. Salant D.J.et al. A new role for complement in experimental membranous nephropathy in rats. J. Clin. Investig. 66:1980;1339-1350.
117. Salerno C.T.et al. A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation. 9:2002;125-134.
118. Scesney S.M.et al. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur. J. Immunol. 26:1996;1729-1735.
119. Smith G.P., Smith R.A. Membrane-targeted complement inhibitors. Mol. Immunol. 38:2001;249-255.
120. Smith R.A. Targeting anticomplement agents. Biochem. Soc. Trans. 30:2002;1037-1041.
121. Soulika A.M.et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin. Immunol. 96:2000;212-221.
122. Sugita Y.et al. Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunology. 82:1994;34-41.
123. Sullivan M.J.et al. The effects of cobra venom factor, an inhibitor of the complement system, on the sequence of morphological events in the rat kidney in experimental pyelonephritis. Yale J. Biol. Med. 50:1977;267-273.
124. Szalai A.J.et al. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol. 164:2000;463-468.
125. Thomas F.et al. Prevention of hyperacute kidney rejection of decomplementation using purified cobra venom factor. J. Surg. Res. 22:1977;189-194.
126. Thomas T.C.et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33:1996;1389-1401.
127. Ueda N.et al. Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system. Inflamm. Res. 49:2000;42-46.
128. Ulevitch R.J.et al. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J. Exp. Med. 142:1975;1570-1590.
129. van den Bogaerde J.et al. Induction of long-term survival of hamster heart xenografts in rats. Transplantation. 52:1991;15-20.
130. Vriesendorp F.J.et al. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J. Neuroimmunol. 58:1995;157-165.
131. Vriesendorp F.J.et al. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis. Int. J. Neurosci. 92:1997;287-298.
132. Wang Y.et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8955-8959.
133. Wang Y.et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8563-8568.
134. Weiler J.M.et al. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. Exp. Med. 147:1978;409-421.
135. Weiler J.M. Polyions regulate the alternative amplification pathway of complement. Immunopharmacology. 6:1983;245-255.
136. Weiler J.M.et al. Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148:1992;3210-3215.
137. Weisman H.F.et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans. Assoc. Am. Phys. 103:1990a;64-72.
138. Weisman H.F.et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990b;146-151.
139. Whiss P.A. Pexelizumab Alexion. Curr. Opin. Investig. Drugs. 3:2002;870-877.
140. Whittum J.A., Lindquist R.R. Mechanisms of cardiac allograft rejection in the inbred rat: the effect of complement depletion by cobra venom factor on hyperacute cardiac allograft rejection. Transplantation. 24:1977;226-228.
141. Woodruff T.M.et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arth. Rheum. 46:2002;2476-2485.
142. Wurzner R.et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm. 8:1991;328-340.
143. Younger J.G.et al. Systemic and lung physiological changes in rats after intravascular activation of complement. J. Appl. Physiol. 90:2001;2289-2295.
144. Zhang H.F.et al. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J. Clin. Investig. 103:1999;55-61.
145. Zhang H.et al. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J. Biol. Chem. 276:2001;27290-27295.
146. Zimmerman J.L.et al. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 28:2000;3149-3154.